Literature DB >> 6147217

The potential value of the sedimentation rate in monitoring treatment outcome in puncture-wound-related Pseudomonas osteomyelitis.

L A Crosby, D A Powell.   

Abstract

Recently, a recommendation was made to treat Pseudomonas osteomyelitis in children with only ten to 14 days of postsurgical antibiotics. However, there were no clinical or laboratory measurements to monitor the response. Fourteen new cases of puncture-wound-related Pseudomonas osteomyelitis of the foot in children were investigated to examine the response of erythrocyte sedimentation rate (ESR) to treatment. The ESR was increased in 12/12 patients with a mean peak of 41 mm/hr and a mean duration of 30 days. After appropriate treatment was begun, the ESR decreased at a mean rate of 1.1 mm/day. In four of five patients with a poor treatment response, the ESR remained elevated until antibiotics were changed (in 3) or surgery performed (in 1). One patient with an abnormal ESR at completion of three weeks of postoperative antibiotics had a relapse after one year. These data suggest a need for careful assessment of treatment response, such as declining ESR, before antibiotics are discontinued at an arbitrary postoperative time period.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6147217

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  3 in total

1.  Wound site as a predictor of complications following deep nail punctures to the foot.

Authors:  M J Patzakis; J Wilkins; W W Brien; V S Carter
Journal:  West J Med       Date:  1989-05

2.  Puncture wound osteochondritis of the foot caused by CDC group Vd.

Authors:  W J Barson; B A Cromer; M J Marcon
Journal:  J Clin Microbiol       Date:  1987-10       Impact factor: 5.948

3.  Factors predictive of relapse in adult bacterial osteomyelitis of long bones.

Authors:  E Garcia Del Pozo; J Collazos; J A Carton; D Camporro; V Asensi
Journal:  BMC Infect Dis       Date:  2018-12-07       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.